Staff editor
The approval is major step forward in the fight against recurrent C. diff infection.
Financing will also support analysis of real-world evidence in people with CF to explore the relationship between P. aeruginosa reduction and clinical outcomes.
David Paez-Espino, Co-founder & CTO at Ancilia Biosciences, discusses the use of CRISPR technology to develop a new class of bacterial therapies that address critical gaps in microbiome-based treatments.
Seres Therapeutics, a leader in the live biotherapeutics space, has received pivotal feedback from the U.S. Food and Drug Administration (FDA) regarding the development of its lead investigational treatment, SER-155,…
Understanding the vaginal microbiome is essential not only for treating gynecological conditions but also for preventing them and promoting overall well-being.
Chris Ford, Senior Vice President, Translational Biology at Seres Therapeutics, discusses the development of SER-155, a cultivated bacterial consortium designed to address the unmet medical need of preventing bloodstream infections…
A comprehensive look at the gut microbiome’s structure, functions, and strategies for sustaining its health.
The discussion with Professor Alessio Fasano highlights the complex interplay between homeostatic, hedonic, and microbiota-driven mechanisms in regulating hunger.
Fecal Microbiota Transplantation (FMT) showing promise beyond C. difficile infection in conditions like IBD, IBS, and metabolic disorders.
Celine Druart, from the Pharmabiotic Research Institute, highlighted critical challenges in the microbiome field, particularly around the standardization of clinical protocols and analytical methods.
